Floatz logo

tx05

Breast Neoplasms

Tanvex BioPharma USA, Inc.Phase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

177 Active assets in the Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Docetaxel
Universitas Airlangga
Phase 4BB
Letrozole
Fujian Cancer Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

tx05 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
58 / 100
View asset →
breast cancerDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →